ChromaDex Appoints Steven D. Rubin, J.D., to its Board of Directors
March 28 2017 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health,
wellness and nutritional ingredients that creates science-based
solutions for dietary supplement, food and beverage, skin care,
sports nutrition, and pharmaceutical products, announced today that
Steven D. Rubin, J.D. has joined the Company’s board of directors.
Mr. Rubin, age 56, has served as OPKO Health, Inc.’s
(NASDAQ:OPK) Executive Vice President – Administration since May
2007 and as a director of since February 2007. Mr. Rubin is a
member of The Frost Group, LLC, a private investment firm. He has
extensive experience as a practicing lawyer, and as general counsel
and board member to multiple public companies.
Mr. Rubin currently serves on the board of directors for the
following companies: VBI Vaccines Inc., a commercial-stage
biopharmaceutical company developing a next generation of vaccines;
Cognit, Inc., a data and analytics company providing cloud-based
mission-critical information and performance marketing solutions;
Kidville, Inc., an operator of large, upscale facilities, catering
to newborns through five-year-old children and their families and
offers a wide range of developmental classes for newborns to
five-year-olds; Non-Invasive Monitoring Systems, Inc., a medical
device company; BioCardia, Inc., a clinical-stage regenerative
medicine company developing novel therapeutics for cardiovascular
diseases; Cocrystal Pharma, Inc., a biotechnology company
developing new treatments for viral diseases; Sevion Therapeutics,
Inc., a clinical stage company which discovers and develops
next-generation biologics for the treatment of cancer and
immunological diseases; Castle Brands, Inc., a developer and
marketer of premium brand spirits; and, Neovasc, Inc., a company
developing and marketing medical specialty vascular devices.
Mr. Rubin previously served as the Senior Vice President,
General Counsel and Secretary of IVAX from August 2001 until
September 2006. Mr. Rubin previously served as a director of the
following companies: Dreams, Inc. (NYSE MKT:DRJ), a vertically
integrated sports licensing and products company; Safestitch
Medical, Inc. prior to its merger with TransEnterix, Inc.; and,
PROLOR Biotech, Inc., prior to its acquisition by the Company in
August 2013.
About ChromaDex: ChromaDex leverages its
complementary business units to discover, acquire, develop and
commercialize patented and proprietary ingredient technologies that
address the dietary supplement, food, beverage, skin care and
pharmaceutical markets. In addition to our ingredient technologies
unit, we also have business units focused on natural product fine
chemicals (known as "phytochemicals"), chemistry and analytical
testing services, and product regulatory and safety consulting. As
a result of our relationships with leading universities and
research institutions, we are able to discover and license early
stage, IP-backed ingredient technologies. We then utilize our
in-house chemistry, regulatory and safety consulting business units
to develop commercially viable ingredients. Our ingredient
portfolio is backed with clinical and scientific research, as well
as extensive IP protection. Our portfolio of patented ingredient
technologies includes NIAGEN® nicotinamide riboside; pTeroPure®
pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal;
IMMULINA™, a spirulina extract; and AnthOrigin™, anthocyanins
derived from a domestically-produced, water-extracted purple corn.
To learn more about ChromaDex, please visit www.ChromaDex.com.
Forward-Looking Statements:
This release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities and
Exchange Act of 1934, as amended, including statements related to
the composition and experience of ChromaDex’s board of directors.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2016, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com
ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024